Jinse Finance reported that MEI Pharma announced the acquisition of 929,548 Litecoin (LTC) at an average purchase price of $107.58, with a total value of approximately $110 million. The company becomes the first publicly listed company in the United States to use Litecoin as a primary reserve asset. Additionally, MEI Pharma has partnered with Litecoin founder Charlie Lee and GSR to launch a $100 million institutional treasury strategy.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
3 Likes
Reward
3
1
Repost
Share
Comment
0/400
Xiniany
· 08-05 13:47
Jinse Finance reported that MEI Pharma announced the acquisition of 929,548 Litecoin (LTC) at an average purchase price of $107.58, with a total value of approximately $110 million. The company becomes the first publicly listed company in the United States to use Litecoin as a primary reserve asset. Additionally, MEI Pharma has partnered with Litecoin founder Charlie Lee and GSR to launch a $100 million institutional treasury strategy.
Jinse Finance reported that MEI Pharma announced the acquisition of 929,548 Litecoin (LTC) at an average purchase price of $107.58, with a total value of approximately $110 million. The company becomes the first publicly listed company in the United States to use Litecoin as a primary reserve asset. Additionally, MEI Pharma has partnered with Litecoin founder Charlie Lee and GSR to launch a $100 million institutional treasury strategy.